{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:42:38Z","timestamp":1794008558917,"version":"4.8.0"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.phrs.2025.108058","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T17:13:09Z","timestamp":1764781989000},"page":"108058","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Poly (ADP-ribose) polymerase (PARP) inhibitors approved for the treatment of cancer"],"prefix":"10.1016","volume":"222","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9861-4139","authenticated-orcid":false,"suffix":"Jr.","given":"Robert","family":"Roskoski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2025.108058_bib1","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1038\/ncomms3240","article-title":"A systematic analysis of the PARP protein family identifies new functions critical for cell physiology","volume":"4","author":"Vyas","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2025.108058_bib2","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.molcel.2015.06.006","article-title":"PARPs and ADP-ribosylation: 50 years \u2026 and counting","volume":"58","author":"Kraus","year":"2015","journal-title":"Mol. Cell"},{"key":"10.1016\/j.phrs.2025.108058_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2025.189282","article-title":"PARP1: A comprehensive review of its mechanisms, therapeutic implications and emerging cancer treatments","volume":"1880","author":"Concei\u00e7\u00e3o","year":"2025","journal-title":"Biochim Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.phrs.2025.108058_bib4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00018-019-03366-0","article-title":"Poly(ADP-ribose) polymerase enzymes and the maintenance of genome integrity","volume":"77","author":"Eisemann","year":"2020","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.phrs.2025.108058_bib5","doi-asserted-by":"crossref","first-page":"4994","DOI":"10.1016\/j.molcel.2021.11.014","article-title":"The BRCT domain of PARP1 binds intact DNA and mediates intrastrand transfer","volume":"81","author":"Rudolph","year":"2021","journal-title":"Mol. Cell"},{"key":"10.1016\/j.phrs.2025.108058_bib6","doi-asserted-by":"crossref","first-page":"5112","DOI":"10.3390\/ijms22105112","article-title":"PARP Power: A structural perspective on PARP1, PARP2, and PARP3 in DNA damage repair and nucleosome remodelling","volume":"22","author":"van Beek","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2025.108058_bib7","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.1093\/nar\/gkz120","article-title":"Poly(ADP-ribosyl)ation by PARP1: reaction mechanism and regulatory proteins","volume":"47","author":"Alemasova","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.phrs.2025.108058_bib8","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMra0804615","article-title":"DNA damage, aging, and cancer","volume":"361","author":"Hoeijmakers","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2025.108058_bib9","doi-asserted-by":"crossref","first-page":"10106","DOI":"10.3390\/ijms262010106","article-title":"DNA damage and repair in pancreatic cancer-The latest findings","volume":"26","author":"Koz\u0142owska","year":"2025","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.phrs.2025.108058_bib10","doi-asserted-by":"crossref","first-page":"9312","DOI":"10.3390\/ijms26199312","article-title":"Mismatch repair deficiency and the role of non-canonical functions in cancer: diagnosis and therapeutic implications","volume":"26","author":"D\u0105browska","year":"2025","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.phrs.2025.108058_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2025.103843","article-title":"Joining of DNA breaks- interplay between DNA ligases and poly (ADP-ribose) polymerases","volume":"149","author":"Call","year":"2025","journal-title":"DNA Repair"},{"key":"10.1016\/j.phrs.2025.108058_bib12","first-page":"9279","article-title":"Poly(ADP-ribose) polymerases covalently modify strand break termini in DNA fragments in vitro","volume":"44","author":"Talhaoui","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.phrs.2025.108058_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2025.103887","article-title":"DNA damage response inhibitors in cancer therapy: mechanisms, clinical development, and combination strategies","volume":"153","author":"Lee","year":"2025","journal-title":"DNA Repair"},{"key":"10.1016\/j.phrs.2025.108058_bib14","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.37818","article-title":"Poly(ADP-ribose) polymerase 1 searches DNA via a 'monkey bar' mechanism","volume":"7","author":"Rudolph","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.phrs.2025.108058_bib15","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s11912-025-01669-z","article-title":"PARP inhibitors in the neoadjuvant setting; A comprehensive overview of the rationale for their use, past and ongoing clinical trials","volume":"27","author":"Habaka","year":"2025","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.phrs.2025.108058_bib16","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2147\/OTT.S499226","article-title":"The Landscape of PARP inhibitors in solid cancers","volume":"18","author":"Muzzana","year":"2025","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.phrs.2025.108058_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108761","article-title":"From bench to bedside: Synthetic strategies and clinical application of PARP inhibitors","volume":"163","author":"Man","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.phrs.2025.108058_bib18","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.phrs.2025.108058_bib19","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1186\/s12885-018-4498-z","article-title":"Changes in ovarian cancer survival during the 20 years before the era of targeted therapy","volume":"18","author":"Lee","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.phrs.2025.108058_bib20","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrc1431","article-title":"BRCA1 and BRCA2: 1994 and beyond","volume":"4","author":"Narod","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2025.108058_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2025.1539880","article-title":"Poly-ADP ribose polymerase (PARP) inhibitor regimens for platinum-sensitive ovarian cancer in randomized, double-blind, phase III controlled trials: protocol for a systematic review and network meta-analysis","volume":"12","author":"Peng","year":"2025","journal-title":"Front. Med."},{"key":"10.1016\/j.phrs.2025.108058_bib22","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.phrs.2025.108058_bib23","article-title":"Unlocking therapeutic potential of poly (adenosine diphosphate ribose) polymerase (PARP) inhibitors in metastatic breast cancer with BRCA gene mutations: a narrative review","volume":"15","author":"Jain","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.phrs.2025.108058_bib24","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1124\/jpet.114.222448","article-title":"Trapping Poly(ADP-Ribose) Polymerase","volume":"353","author":"Shen","year":"2015","journal-title":"J. Pharm. Exp. Ther."},{"key":"10.1016\/j.phrs.2025.108058_bib25","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1146\/annurev-cancerbio-030518-055914","article-title":"PARP trapping beyond homologous recombination and platinum sensitivity in cancers","volume":"3","author":"Murai","year":"2019","journal-title":"Annu Rev. Cancer Biol."},{"key":"10.1016\/j.phrs.2025.108058_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107534","article-title":"Targeted and cytotoxic inhibitors used in the treatment of breast cancer","volume":"210","author":"Roskoski","year":"2024","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2025.108058_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.103000","article-title":"The emerging role of PARP inhibitors in prostate cancer: a narrative review","volume":"140","author":"Lobianco","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.phrs.2025.108058_bib28","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1126\/science.97.2529.541","article-title":"Endocrine control of prostatic cancer","volume":"97","author":"Huggins","year":"1943","journal-title":"Science"},{"key":"10.1016\/j.phrs.2025.108058_bib29","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3390\/cancers11030352","article-title":"BRCA2 and Other DDR Genes in Prostate Cancer","volume":"11","author":"Nombela","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.phrs.2025.108058_bib30","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.3390\/jcm14041129","article-title":"Current and emerging treatment options for pancreatic cancer: a comprehensive review","volume":"14","author":"Hayat","year":"2025","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.phrs.2025.108058_bib31","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1021\/acs.jmedchem.4c02642","article-title":"The potential of PARP inhibitors as antitumor drugs and the perspective of molecular design","volume":"68","author":"Wang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2025.108058_bib32","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40265-015-0345-6","article-title":"Olaparib: first global approval","volume":"75","author":"Deeks","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2025.108058_bib33","doi-asserted-by":"crossref","first-page":"7165","DOI":"10.1158\/1078-0432.CCR-17-1337","article-title":"FDA Approval summary: Rucaparib for the treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer","volume":"23","author":"Balasubramaniam","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2025.108058_bib34","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1158\/1078-0432.CCR-18-0042","article-title":"FDA approval summary: Niraparib for the maintenance treatment of patients with recurrent ovarian cancer in response to platinum-based chemotherapy","volume":"24","author":"Ison","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2025.108058_bib35","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1007\/s40265-018-1026-z","article-title":"Talazoparib: First global approval","volume":"78","author":"Hoy","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2025.108058_bib36","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1158\/1078-0432.CCR-21-1186","article-title":"Pamiparib monotherapy for patients with germline BRCA1\/2-mutated ovarian cancer previously treated with at least two lines of chemotherapy: a multicenter, open-label, Phase II study","volume":"28","author":"Wu","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2025.108058_bib37","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1358\/dot.2022.58.6.3389001","article-title":"Pamiparib for germline BRCA mutation-associated recurrent advanced ovarian, fallopian tube or primary peritoneal cancer","volume":"58","author":"Skrzypczyk-Ostaszewicz","year":"2022","journal-title":"Drugs Today"},{"key":"10.1016\/j.phrs.2025.108058_bib38","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40265-021-01541-x","article-title":"Fuzuloparib: First approval","volume":"81","author":"Lee","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2025.108058_bib39","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1158\/1535-7163.MCT-23-0625","article-title":"The discovery of a potent PARP1 inhibitor senaparib","volume":"24","author":"Cai","year":"2025","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2025.108058_bib40","article-title":"Cost in the United States of FDA-approved small molecule protein kinase inhibitors used in the treatment of neoplastic and non-neoplastic diseases","volume":"199","author":"Roskoski","year":"2023","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2025.108058_bib41","first-page":"5693","article-title":"Financial toxicity and employment status in cancer survivors. A systematic literature review","volume":"28","author":"Mols","year":"2020","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.phrs.2025.108058_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106774","article-title":"Rule of five violations among the FDA-approved small molecule protein kinase inhibitors","volume":"191","author":"Roskoski","year":"2023","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2025.108058_bib43","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.phrs.2025.108058_bib44","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S1359-6446(04)03069-7","article-title":"Ligand efficiency: a useful metric for lead selection","volume":"9","author":"Hopkins","year":"2004","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.phrs.2025.108058_bib45","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/nrd2445","article-title":"The influence of drug-like concepts on decision-making in medicinal chemistry","volume":"6","author":"Leeson","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2025.108058_bib46","doi-asserted-by":"crossref","first-page":"6401","DOI":"10.1021\/acs.jmedchem.8b00077","article-title":"Lipophilic efficiency as an important metric in drug design","volume":"61","author":"Johnson","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2025.108058_bib47","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nrd4163","article-title":"The role of ligand efficiency metrics in drug discovery","volume":"13","author":"Hopkins","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2025.108058_bib48","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.addr.2016.01.018","article-title":"Molecular inflation, attrition, and the rule of five","volume":"101","author":"Leeson","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.phrs.2025.108058_bib49","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2025.108058_bib50","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1023\/A:1008130001697","article-title":"Property distribution of drug-related chemical databases","volume":"14","author":"Oprea","year":"2000","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.phrs.2025.108058_bib51","doi-asserted-by":"crossref","first-page":"7210","DOI":"10.1021\/acs.jmedchem.1c00416","article-title":"Target-based evaluation of \"drug-like\" properties and ligand efficiencies","volume":"64","author":"Leeson","year":"2021","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2025.108058_bib52","first-page":"3559","article-title":"The first general index of molecular complexity","volume":"1103","author":"Bertz","year":"1981","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.phrs.2025.108058_bib53","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1021\/ci00054a004","article-title":"Molecular complexity: a simplified formula adapted to individual atoms","volume":"27","author":"Hendrickson","year":"1987","journal-title":"J. Chem. Inf. Comput. Sci."},{"key":"10.1016\/j.phrs.2025.108058_bib54","doi-asserted-by":"crossref","first-page":"7206","DOI":"10.1021\/jm500515d","article-title":"Physicochemical descriptors of aromatic character and their use in drug discovery","volume":"57","author":"Ritchie","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2025.108058_bib55","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.drudis.2016.07.007","article-title":"Quality guidelines for oral drug candidates: dose, solubility and lipophilicity","volume":"21","author":"Bayliss","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.phrs.2025.108058_bib56","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.trecan.2024.06.008","article-title":"PARPi, BRCA, and gaps: controversies and future research","volume":"10","author":"Dibitetto","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.phrs.2025.108058_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2025.101287","article-title":"Targeting DNA damage response pathways in tumor drug resistance: Mechanisms, clinical implications, and future directions","volume":"83","author":"Zhu","year":"2025","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.phrs.2025.108058_bib58","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1200\/JCO.2010.34.2980","article-title":"Secondary somatic mutations restoring BRCA1\/2 predict chemotherapy resistance in hereditary ovarian carcinomas","volume":"29","author":"Norquist","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2025.108058_bib59","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1158\/1078-0432.CCR-22-3715","article-title":"Investigation of PARP inhibitor resistance based on serially collected circulating tumor DNA in patients with BRCA-mutated ovarian cancer","volume":"29","author":"Kim","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2025.108058_bib60","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.eururo.2022.09.010","article-title":"Emergence of BRCA reversion mutations in patients with metastatic castration-resistant prostate cancer after treatment with rucaparib","volume":"83","author":"Loehr","year":"2023","journal-title":"Eur. Urol."},{"key":"10.1016\/j.phrs.2025.108058_bib61","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1158\/2159-8290.CD-17-0146","article-title":"Analysis of circulating cell-free DNA identifies multiclonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors","volume":"7","author":"Quigley","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.phrs.2025.108058_bib62","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.ccell.2018.05.008","article-title":"Selective loss of PARG restores PARylation and counteracts PARP inhibitor-mediated synthetic lethality","volume":"33","author":"Gogola","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.phrs.2025.108058_bib63","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"PRIMA\/ENGOT-OV26\/GOG-3012 Investigators, Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2025.108058_bib64","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12943-025-02355-1","article-title":"Clinical approaches to overcome PARP inhibitor resistance","volume":"24","author":"Zou","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.phrs.2025.108058_bib65","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1200\/JCO.2008.21.2134","article-title":"American Society of Clinical Oncology, Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology","volume":"27","author":"Winer","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2025.108058_bib66","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/annonc\/mdw133","article-title":"Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1\/2 mutation: A multistudy analysis of response rates and safety","volume":"27","author":"Matulonis","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.phrs.2025.108058_bib67","article-title":"Epigenetic mechanisms of PARP inhibitor resistance in ovarian cancer: A systematic review with bioinformatic analysis of clinically actionable genes","volume":"217","author":"Habiburrahman","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.phrs.2025.108058_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14737140.2025.2575825","article-title":"Drugging the DNA damage response in the clinic: going beyond PARP","volume":"1","author":"Torrado","year":"2025","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.phrs.2025.108058_bib69","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.phrs.2017.02.005","article-title":"Guidelines for preparing color figures for everyone including the colorblind","volume":"119","author":"Roskoski","year":"2017","journal-title":"Pharm. Res."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825004839?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825004839?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T23:42:52Z","timestamp":1766187772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661825004839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":69,"alternative-id":["S1043661825004839"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2025.108058","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Poly (ADP-ribose) polymerase (PARP) inhibitors approved for the treatment of cancer","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2025.108058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108058"}}